Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Chemotherapy and Autologous Stem Cell Reconstitution for Glioblastoma Multiforme or Diffuse Intrinsic Brainstem Tumors
NCT00002619Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 1994
- Primary completion
- Apr 2000
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa and carboplatin in glioblastoma multiforme (GBM) and brainstem tumor (BSG), sponsored by NYU Langone Health. Primary endpoints: Overall Survival, Progression-Free Interval and 4 more. Started Sep 1994; status: completed.
02
Drugs
thiotepacarboplatin
03
Conditions
glioblastoma multiforme (GBM)brainstem tumor (BSG)
Beyond the preview
Go deeper on NCT00002619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002619.